vadimezan has been researched along with clodronic acid in 1 studies
| Studies (vadimezan) | Trials (vadimezan) | Recent Studies (post-2010) (vadimezan) | Studies (clodronic acid) | Trials (clodronic acid) | Recent Studies (post-2010) (clodronic acid) |
|---|---|---|---|---|---|
| 272 | 16 | 101 | 1,748 | 210 | 477 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aghaei, M; Downey, CM; Jirik, FR; Schwendener, RA | 1 |
1 other study(ies) available for vadimezan and clodronic acid
| Article | Year |
|---|---|
DMXAA causes tumor site-specific vascular disruption in murine non-small cell lung cancer, and like the endogenous non-canonical cyclic dinucleotide STING agonist, 2'3'-cGAMP, induces M2 macrophage repolarization.
Topics: Adenocarcinoma; Animals; Carcinoma, Non-Small-Cell Lung; Cell Membrane Permeability; Cell Polarity; Clodronic Acid; Humans; Inflammation; Liposomes; Lung Neoplasms; Macrophages; Male; Membrane Proteins; Mice, Transgenic; Necrosis; Neovascularization, Pathologic; Nucleotides, Cyclic; Phenotype; ras Proteins; Subcutaneous Tissue; Tumor Suppressor Protein p53; Xanthones; Xenograft Model Antitumor Assays | 2014 |